RGLS REGULUS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended March 31, 2025, REGULUS THERAPEUTICS INC reported revenue of n/a, net income of −$9.63M and diluted EPS of −$0.15; for the fiscal year ended December 2024 revenue was n/a.
RGLS annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$50.0M, net income −$46.4M (margin n/a), EPS −$0.82
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$31.1M, net income −$30.0M (margin n/a), EPS −$1.58
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$28.2M, net income −$28.3M (margin n/a), EPS $1.86
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$27.8M, net income −$27.8M (margin n/a), EPS $3.24
RGLS quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$9.63M, EPS −$0.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.8M, EPS −$0.15
- Quarter ended Sep 30, 2024: revenue n/a, net income −$14.1M, EPS −$0.21
- Quarter ended Jun 30, 2024: revenue n/a, net income −$11.0M, EPS −$0.17
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.47M, EPS −$0.29
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.06M, EPS −$0.39
- Quarter ended Sep 30, 2023: revenue n/a, net income −$7.82M, EPS −$0.40
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.01M, EPS −$0.37
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.14M, EPS −$0.42
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$6.80M, EPS $3.32
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.55M, EPS −$0.50
- Quarter ended Jun 30, 2022: revenue n/a, net income −$7.26M, EPS −$0.50
- Quarter ended Mar 31, 2022: revenue n/a, net income −$6.72M, EPS −$0.46
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$7.13M, EPS $5.09
- Quarter ended Sep 30, 2021: revenue $0, net income −$8.63M, EPS −$0.99
- Quarter ended Jun 30, 2021: revenue $0, net income −$6.03M, EPS −$0.78
- Quarter ended Mar 31, 2021: revenue $0, net income −$6.01M, EPS −$0.08
RGLS cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$41.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$26.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$25.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$24.1M, share buybacks n/a
RGLS balance sheet
- Mar 31, 2025: cash $49.5M, total assets $74.8M, total liabilities $5.80M, shareholders' equity $69.0M
- Dec 31, 2024: cash $38.5M, total assets $84.2M, total liabilities $7.77M, shareholders' equity $76.4M
- Sep 30, 2024: cash $26.4M, total assets $93.8M, total liabilities $6.96M, shareholders' equity $86.8M
- Jun 30, 2024: cash $17.1M, total assets $104M, total liabilities $5.94M, shareholders' equity $98.2M
- Mar 31, 2024: cash $29.6M, total assets $114M, total liabilities $6.55M, shareholders' equity $108M
- Dec 31, 2023: cash $23.8M, total assets $30.8M, total liabilities $9.56M, shareholders' equity $21.2M
- Sep 30, 2023: cash $25.8M, total assets $37.7M, total liabilities $9.49M, shareholders' equity $28.3M
- Jun 30, 2023: cash $37.3M, total assets $43.6M, total liabilities $9.65M, shareholders' equity $34.0M
Is RGLS profitable?
No. REGULUS THERAPEUTICS INC lost $47.5M over the last four quarters.
What is RGLS's EPS?
Diluted earnings per share over the last four quarters were −$0.68; −$0.15 in the latest quarter.